Objective To investigation the efficacy and safety of prolonged intermittent renal replacement therapy (PIRRT) to substitute for maintenance hemodialysis (MHD). Methods Clinical data of the patients treated with renal replacement therapy in the 940th Hospital of Joint Logistics Support Force of Chinese PLA between Oct. 2022 to Mar. 2023, at which quarantine procedures were carried out for the epidemic of coronavirus 2019 disease, were retrospectively studied. The patients undergoing pre- and post-dilution of accelerated venovenous hemofiltration (AVVH) were divided into two groups according to the dialysis dose: low-dose group [25～30ml/(kg·h)] and high-dose group [50～60ml/(kg·h)]. Treatment parameters for the first PIRRT, serum levels of urea, K+, PO4 and carbon dioxide at the beginning and end of PIRRT, estimated urea reduction rate (URR), spKt/V, and complications occurring during and after PIRRT were collected and compared between the two groups. Results There were no significant differences in age, sex ratio, dry body weight and hemoglobin (t=1.388, 0.459, 0.479 and 0.913 respectively, P=0.085, 0.498, 0.683 and 0.818 respectively) between low-dose group (n=31) and high-dose group (n=36). Blood flow rate of PIRRT, treatment dose and filter fraction were significantly higher in high-dose group than in low-dose group (t =14.535, 39.358 and 7.304 respectively, P＜0.001); while total net ultrafiltration had no difference between the two groups (t =1.076, P=0.857). Serum K+, PO4, and carbon dioxide were corrected to normal ranges at the end of PIRRT in both groups. URR and spKt/V were significant higher in high-dose group than in low-dose group (t=12.039 and 5.145, P<0.001). No complications were observed during and after PIRRT. Conclusions PIRRT can effectively correct volume overload, electrolyte abnormalities and acid-base imbalance. High-dose PIRRT is more effective than low-dose PIRRT in removal of uremic toxins, and is well tolerated by the patients and suitable to substitute for MHD.
XI Chun-Sheng
,
WANG Jin-Han
,
CAI Rui-Lian
,
FANG Chun-Tian
,
XIAO Liao-Yuan
,
LIU Fei
,
GAO Jian
. Clinical investigation of prolonged intermittent renal replacement therapy to substitute for maintenance hemodialysis[J]. Chinese Journal of Blood Purification, 2024
, 23(04)
: 282
-285
.
DOI: 10.3969/j.issn.1671-4091.2024.04.009
[1] Zoraster R, Vanholder R, Hansra RS, et al. Disaster management of chronic dialysis patients [J]. Am J Disaster Med, 2007, 2(2):96-106.
[2] Kleinpeter MA. Disaster preparedness for dialysis patients[J]. Clin J Am Soc Nephrol, 2011, 6(10): 2337-2339.
[3] Foster M, Brice JH, Shofer F, et al. Personal disaster preparedness of dialysis patients in North Carolina[J]. Clin J Am Soc Nephrol, 2011, 6(10): 2478-2484.
[4] Yessayan LT, Heung M, Girard FA, et al. Deployment of a new CRRT/PIRRT device during the COVID-19 pandemic emergency: organizational challenges and implementation results[J]. Blood Purif, 2021, 50 (3):390-398.
[5] Boparai S, Netzel A, Hansra RS, et al. Dialysis in disaster: Using continuous renal replacement therapy for end-stage renal disease patients, a pilot proof of concept study[J]. Am J of Emergency Med, 2022, 58, 351.e1-351.e2.
[6] 许晶，吕佳颐，崔方正，等. 新型冠状病毒流行下连续性肾脏替代治疗用于维持性血液透析的初探[J]. 肾脏病与透析肾移植杂志，2022, 31(5): 414-419.
[7] 魏文倩，戎殳. 延长的间歇性肾脏替代治疗[J].中国血液净化，2018, 17(9):621-625.
[8] Sethi SK, Mittal A, Nair N, et al. Pediatric continuous renal replacement therapy (PCRRT) expert committee recommendation on prescribing prolonged intermittent renal replacement therapy (PIRRT) in critically ill children[J]. Hemodial Int, 2020, 24(2):237-251.
[9] Levine Z, Vijayan A. Prolonged intermittent kidney replacement therapy[J]. Clin J Am Soc Nephrol, 2023, 18(3): 383-391.
[10] Clark EG, Vijayan A. How I prescribe prolonged intermittent renal replacement therapy[J]. ?Crit Care, 2023, 27(1):88.
[11] Bello AK, Okpechi IG, Osman MA, et al. Epidemiology of haemodialysis outcomes[J]. Nat Rev Nephrol, 2022, 18(6):378-395.
[12] Gaudry S, Palevsky PM, Dreyfuss D. Extracorporeal kidney-replacement therapy for acute kidney injury[J]. N Engl J Med, 2022, 386(10):964-975.
[13] 中国医师协会肾脏病医师分会血液透析充分性协作组. 中国血液透析充分性临床实践指南[J]. 中华医学杂志，2015, 95(34):2748-2753.
[14] Chan RJ, Helmeczi W, Canney M, et al. Management of intermittent hemodialysis in the critically ill patient[J]. Clin J Am Soc Nephrol, 2023, 18(2):245-255.
[15] Murugan R, Hoste E, Mehta RL, et al. Precision fluid management in continuous renal replacement therapy[J]. Blood Purif, 2016, 42(3): 266-278.
[16]Karkar A, Ronco C. Prescription of CRRT: a pathway to optimize therapy[J]. ?Ann Intensive Care, 2020, 10 (1):32.
[17] Neyra JA, Tolwani A. CRRT prescription and delivery of dose[J]. Semin Dial, 2021, 34(6): 432-439.
[18] Teixeira JP, Neyra JA, Tolwani A. Continuous KRT: a contemporary review[J]. Clin J Am Soc Nephrol, 2023, 18(2):256-269.
[19] Bagshaw SM, Chakravarthi MR, Ricci Z, et al. Precision continuous renal replacement therapy and solute control[J]. Blood Purif, 2016, 42(3): 238-247.
